


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
ENTERED INTO EXCLUSIVE COMMERCIAL COOPERATION AGREEMENT
WITH BOAN BIOTECH

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**” or “**Sino Biopharm**”) announces that CP Pharmaceutical (Qingdao) Co., Ltd. (“**CP Qingdao**”), a subsidiary of the Company, entered into an exclusive commercial cooperation agreement with Shandong Boan Biotechnology Co., Ltd. (“**Boan Biotech**”), pursuant to which, CP Qingdao has been granted the exclusive commercialisation rights for Denosumab Injection (“**Boyoubei®**”) in Mainland China by Boan Biotech. The authorization period under the agreement is five years, after the expiry of which CP Qingdao shall have the priority to renew the commercialization authorization of this product on the same conditions.

Boyoubei® is a denosumab injection developed by Boan Biotech, which was approved by the National Medical Products Administration of China in November 2022 for the treatment of postmenopausal women with osteoporosis at high risk of fracture; it can significantly reduce the risk of vertebral, non-vertebral and hip fractures in postmenopausal women. Boyoubei® is the first biosimilar to Prolia® approved for marketing in the world. Based on public information, Prolia® generated global sales of US\$3,248 million in 2021 with an annual growth rate of 18%, having a huge market demand.

The active ingredient of Boyoubei® is a human immunoglobulin G2 monoclonal antibody of the RANK ligand, which can block RANKL activating osteoclasts and the receptor RANK on the surface of its precursors. Blocking the RANKL/RANK interaction can inhibit the formation, function and survival of osteoclasts, thereby reducing bone resorption and increasing bone mass and strength in the bone cortex and trabeculae.

CP Qingdao, a subsidiary of Sino Biopharm, has been focusing on the field of osteoporosis for many years and has a wide range of products, with its core product occupying a leading position in the Chinese market. Boyoubei® can form a competitive product portfolio with CP Qingdao's existing products in this field to create greater synergy. With its professional commercialization and extensive clinical endpoint coverage team in the field of osteoporosis, CP Qingdao will accelerate the commercialization of Boyoubei® to meet the urgent clinical needs of Chinese patients.

ABOUT BOAN BIOTECH

Boan Biotech is a fully integrated biopharmaceutical company listed on The Stock Exchange of Hong Kong Limited (stock code: 6955). It specializes in therapeutic antibody development, manufacturing and commercialization with a focus on oncology, autoimmunity, ophthalmology and metabolic diseases. Boan Biotech's antibody discovery activities are organized around three platforms, namely Human Antibody Transgenic Mouse and Phage Display Technology Platform, Bispecific T-cell Engager Technology Platform and ADC Technology Platform. Boan Biotech has developed extensive experience in areas of antibody discovery, cell line development, upstream and downstream process development, analytical and bio-analytical method development, technology transfer as well as pilot and commercial scale production. Currently, Boan Biotech has developed several innovative antibody products with international intellectual property protection and biosimilar products. Two of these products are already in the commercialization stage.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 10 January 2023

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.